News & Events
US FDA Accepts Investigational New Drug Application for Coya Therapeutics’ Experimental Therapy for FTD
Biotechnology company Coya Therapeutics announced that the United States Food and Drug Administration had accepted its investigational new drug (IND) application for its COYA 302 experimental therapy for FTD. The…
Advancing Hope: FTD Staff attend the Amyotrophic Lateral Sclerosis Motor Neuron Disease Annual Symposium
Shana Dodge, PhD, AFTD’s Director of Research Engagement, and Kim Jenny, MS, LCGC, AFTD’s Manager of Genetic Initiatives, attended the Amyotrophic Lateral Sclerosis Motor Neuron Disease Annual Symposium, held in…
Dear HelpLine: Compulsive Sexual Behavior
Dear HelpLine, My spouse with bvFTD has some behaviors that are difficult to talk about. He is obsessed with pornography, which is very different than who he used to be.…
Prevail Therapeutics Discontinues PR006 Trial
On February 4, Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly & Co., announced the discontinuation of the PR006 “PROCLAIM” drug development program for FTD with GRN variants due…
GUIDE: A New Medicare Pilot Program Can Help Families Facing FTD
Professionals who work in the community know that dementia support services can be fragmented and difficult for families to navigate. Needed services are often provided by a variety of different…
FTD Call To Action Featured In Canadian Media
In an opinion piece published recently in the Edmonton (Alberta, CA) Journal, Naomi Mison called for reform of the bureaucracy and improvement of dementia care access in Canada. She should know: Her…
AARP Highlights What FTD Caregivers Need to Know
It’s subtle changes in speech and behavior, not memory loss, that is often the first sign of FTD, said AARP in a recent article on its website. FTD is less…
AFTD Grantee Contributes to Study on Impact of Neuropsychiatric Symptoms in PSP
A study published in the European Journal of Neurology analyzes the impact of neuropsychiatric symptoms like depression and anxiety on the quality of life of people living with progressive supranuclear…
